16.48MMarket Cap-538P/E (TTM)
0.621High0.600Low71.93KVolume0.621Open0.610Pre Close43.80KTurnover0.34%Turnover RatioLossP/E (Static)27.11MShares3.70052wk High0.59P/B12.76MFloat Cap0.50052wk Low--Dividend TTM20.98MShs Float17.990Historical High--Div YieldTTM3.44%Amplitude0.500Historical Low0.608Avg Price1Lot Size
Galecto Stock Forum
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
@FiReBiTriXiE @jimmy the trader @MangoXXX @PYUN970IHaveChosen @Ripper @Rivera @Trytosaveabit @VinylEagle @Wind_Storm @8 Seconds
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AH volume 1.2M and growing
positive trial data 👍
2 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
No comment yet